Targeted therapy, which has radically altered the treatment of late-stage RCC in recent years, relies on the following two main groups of agents: vascular endothelial growth factor (VEGF)-targeting drugs and mammalian target of rapamycin (mTOR) inhibitors. Here, VEGFA is linked to renal cell carcinoma.